Literature DB >> 3587367

Prospects for the control of AIDS by immunizing seropositive individuals.

J Salk.   

Abstract

The long incubation period between infection and the development of clinical AIDS may be due to an immune response to the initial infection which persists with health and wanes with disease. If this response can be boosted, it may be possible to reduce the viral burden, prevent the development of disease and reduce contagiousness.

Entities:  

Mesh：

Year:  1987        PMID： 3587367     DOI： 10.1038/327473a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  20 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.

Authors:  R J Ho; R L Burke; T C Merigan
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

5.  Serum HIV antigen and anti-P24-antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets.

Authors:  J M Andrieu; D Eme; A Venet; C Audroin; J M Tourani; M Stern; D Israel-Biet; K Beldjord; F Driss; P Even
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

6.  Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

Authors:  R B Moss; F Ferre; A Levine; J Turner; F C Jensen; A E Daigle; S P Richieri; A Truckenbrod; R J Trauger; D J Carlo; J Salk
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

7.  Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

Authors:  C J Gibbs; R Peters; M Gravell; B K Johnson; F C Jensen; D J Carlo; J Salk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.